Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
DJ Drucker - Diabetes Care, 2024 - Am Diabetes Assoc
The development of glucagon-like peptide 1 receptor agonists (GLP-1RA) for type 2
diabetes and obesity was followed by data establishing the cardiorenal benefits of GLP-1RA …
diabetes and obesity was followed by data establishing the cardiorenal benefits of GLP-1RA …
A review of MASLD-related hepatocellular carcinoma: progress in pathogenesis, early detection, and therapeutic interventions
Y Ma, J Wang, W Xiao, X Fan - Frontiers in Medicine, 2024 - frontiersin.org
The incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) is
continuously rising, evolving into a global health challenge. Concurrently, cases of …
continuously rising, evolving into a global health challenge. Concurrently, cases of …
Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study
Objective To investigate whether use of glucagon-like peptide 1 (GLP1) receptor agonists is
associated with increased risk of thyroid cancer. Design Scandinavian cohort study. Setting …
associated with increased risk of thyroid cancer. Design Scandinavian cohort study. Setting …
Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated Steatotic liver disease …
Summary Background/Aims We examined the effects of glucagon‐like peptide‐1 receptor
agonists (GLP‐1RAs) initiation on long‐term Adverse Liver Outcomes (ALO) in patients with …
agonists (GLP‐1RAs) initiation on long‐term Adverse Liver Outcomes (ALO) in patients with …
Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists and cancer mortality. A real-world registry
D García-Vega, S Cinza-Sanjurjo… - Revista Española de …, 2024 - Elsevier
Introduction and objectives: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and
glucagon-like peptide-1 receptor agonists (GLP1ra) reduce cardiovascular events through …
glucagon-like peptide-1 receptor agonists (GLP1ra) reduce cardiovascular events through …
Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC
Z Li, Y Zhang, Y Li, J Lan, Y Hu, J Yu, Q Meng… - Hepatology, 2024 - journals.lww.com
To the editor, The glucagon-like peptide-1 (GLP-1) receptor agonists were listed as the top
of Science's 2023 Breakthrough of the Year on December 15, 2023. With great interest, we …
of Science's 2023 Breakthrough of the Year on December 15, 2023. With great interest, we …
Is the evidence convincing for the expansion of CHB treatment criteria to reduce the risk of HCC?
Z Li, Y Zhang, Y Li, X Chen, J Hu, J Yu, Y Hu, S Nie… - Hepatology, 2024 - journals.lww.com
To the Editor: Finding and removing the risk factors is one of the optimal strategies for global
prevention of hepatocellular carcinoma (HCC). With great enthusiasm, we read the …
prevention of hepatocellular carcinoma (HCC). With great enthusiasm, we read the …
Glucagon-like peptide 1 receptor agonists for treatment of steatotic liver disease in patients with Type 2 diabetes mellitus: growing evidence but not yet there
P Ginès, M Serra-Burriel - Gastroenterology, 2024 - gastrojournal.org
These drugs act as agonists of GLP-1, a peptide synthesized by endocrine cells of the small
intestine and colon, that produces effects in the pancreas, such as increasing glucose …
intestine and colon, that produces effects in the pancreas, such as increasing glucose …
Glucagon-like Peptide 1 Receptor Agonist Use and Risk of Thyroid Cancer: Scandinavian Cohort Study
C Jonasson - 2023 - bmj.com
Confidential: For Review Only Page 1 Confidential: For Review Only Glucagon-like Peptide 1
Receptor Agonist Use and Risk of Thyroid Cancer: Scandinavian Cohort Study Journal: BMJ …
Receptor Agonist Use and Risk of Thyroid Cancer: Scandinavian Cohort Study Journal: BMJ …
The causal analysis of missing confounding-factors for the association between HDV with specific liver events
Z Li, Y Zhang, Y Li, J Lan, Y Hu, Q Meng, L Nadeem… - Hepatology - journals.lww.com
To the Editor: What is the actual role of hepatitis delta virus (HDV) in liver morbidity and
mortality? With great interest, we read the relevant investigation by Gish et al. recently …
mortality? With great interest, we read the relevant investigation by Gish et al. recently …